{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Esophagus&page=8", "query": { "condition": "Adenocarcinoma Esophagus", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 325, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Esophagus&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Esophagus&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T19:48:13.961Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02205463", "title": "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Stomach Cancer" ], "interventions": [ { "name": "KD019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-12", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2014-08-01", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02205463" }, { "nct_id": "NCT04907643", "title": "Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Pain", "Visceral Pain", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Small Intestine Cancer", "Pancreas Cancer", "Liver Cancer", "Colon Cancer", "Biliary Tract Cancer", "Stomach Cancer", "Rectum Cancer", "Peritoneal Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Cancers - Anus", "Gastrointestinal Cancers - Stomach", "Gastrointestinal Cancers - Colorectal", "Gastrointestinal Cancers - Small Intestine", "Small Intestine Cancer Stage III", "Small Intestine Cancer Stage IV", "Small Intestine Cancer, Recurrent", "Pancreas Cancer, Stage III", "Pancreas Cancer, Stage IV", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Liver Cancer Stage IIIa", "Liver Cancer Stage IIIb", "Liver Cancer Stage IIIc", "Liver Cancer Stage IV", "Colon Cancer Stage III", "Colon Cancer Stage IV", "Stomach Cancer Stage III", "Stomach Cancer Stage IV", "Stomach Cancer Recurrent", "Rectum Cancer, Recurrent", "Gastrointestinal Cancers - Liver", "Anal Cancer", "Anal Cancer Stage III", "Anal Cancer Stage IV", "Anal Cancer Recurrent", "Anal Cancer Metastatic", "Anal Cancer, Stage IIIA", "Anal Cancer, Stage IIIB", "Appendix Cancer", "Ampullary Cancer", "Bile Duct Cancer", "Bile Duct Cancer Stage III", "Bile Duct Cancer Stage IV", "Bile Duct Cancer Stage IVA", "Bile Duct Cancer Stage IVB", "Bile Duct Cancer Recurrent", "Carcinoid Tumor", "Carcinoid Tumor of Pancreas", "Carcinoid Tumor of Large Intestine", "Carcinoid Tumor of GI System", "Carcinoid Tumor of Colon", "Carcinoid Tumor of Liver", "Carcinoid Tumor of Cecum", "Carcinoid Tumor of Ileum", "Carcinoid Tumor of Rectum", "Carcinoid Tumor of the Small Bowel", "Carcinoid Tumor of the Stomach", "Large Intestine Cancer", "Esophagus Cancer", "Esophagus Cancer, Stage III", "Esophagus Cancer, Stage IV", "Esophagus Cancer, Recurrent", "Gallbladder Cancer", "Gallbladder Cancer Stage III", "Gallbladder Cancer Stage IV", "Gastric (Stomach) Cancer", "Neuroendocrine Tumor", "Peritoneum Cancer", "Rectal Cancer", "Esophagus Cancer, Stage I", "Esophagus Cancer, Stage II", "Gallbladder Cancer Stage I", "Gallbladder Cancer Stage II", "Bile Duct Cancer Stage I", "Bile Duct Cancer Stage II" ], "interventions": [ { "name": "PICO G2 4k", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 360, "start_date": "2021-10-05", "completion_date": "2027-03-16", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04907643" }, { "nct_id": "NCT02344810", "title": "C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Gastrointestinal Cancer", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "c-Met inhibitor AMG 337", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-03-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02344810" }, { "nct_id": "NCT06340711", "title": "Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "OBP-301", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-04-25", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 2, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06340711" }, { "nct_id": "NCT06044311", "title": "Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma Esophagus", "Locally Advanced Adenocarcinoma", "Siewert Type I Adenocarcinoma of Esophagogastric Junction", "Siewert Type II Adenocarcinoma of Esophagogastric Junction" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Standard of Care Preoperative Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melissa Lumish", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-09-30", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06044311" }, { "nct_id": "NCT00003192", "title": "Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "aminocamptothecin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1998-03", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 7, "location_summary": "Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003192" }, { "nct_id": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "TJ033721 (givastomig)", "type": "DRUG" }, { "name": "TJ033721 (givastomig) , nivolumab, chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), durvalumab, chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2021-06-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Layfayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900818" }, { "nct_id": "NCT00268346", "title": "Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "ZD1839", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2005-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2016-01-05", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268346" }, { "nct_id": "NCT01393483", "title": "Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "serum and tissue mesothelin", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 371, "start_date": "2011-03", "completion_date": "2024-10-22", "has_results": false, "last_update_posted_date": "2024-10-28", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393483" }, { "nct_id": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "ABT-806", "type": "DRUG" }, { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Standard cytotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-01-20", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-14T19:48:13.961Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213289" } ] }